Suppr超能文献

青少年肥胖:综述。

Obesity in Adolescents: A Review.

机构信息

Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis.

Department of Pediatrics, Department of Population Health Sciences, Duke University, Durham, North Carolina.

出版信息

JAMA. 2024 Sep 3;332(9):738-748. doi: 10.1001/jama.2024.11809.

Abstract

IMPORTANCE

Obesity affects approximately 21% of US adolescents and is associated with insulin resistance, hypertension, dyslipidemia, sleep disorders, depression, and musculoskeletal problems. Obesity during adolescence has also been associated with an increased risk of mortality from cardiovascular disease and type 2 diabetes in adulthood.

OBSERVATIONS

Obesity in adolescents aged 12 to younger than 18 years is commonly defined as a body mass index (BMI) at the 95th or greater age- and sex-adjusted percentile. Comprehensive treatment in adolescents includes lifestyle modification therapy, pharmacotherapy, and metabolic and bariatric surgery. Lifestyle modification therapy, which includes dietary, physical activity, and behavioral counseling, is first-line treatment; as monotherapy, lifestyle modification requires more than 26 contact hours over 1 year to elicit approximately 3% mean BMI reduction. Newer antiobesity medications, such as liraglutide, semaglutide, and phentermine/topiramate, in combination with lifestyle modification therapy, can reduce mean BMI by approximately 5% to 17% at 1 year of treatment. Adverse effects vary, but severe adverse events from these newer antiobesity medications are rare. Surgery (Roux-en-Y gastric bypass and vertical sleeve gastrectomy) for severe adolescent obesity (BMI ≥120% of the 95th percentile) reduces mean BMI by approximately 30% at 1 year. Minor and major perioperative complications, such as reoperation and hospital readmission for dehydration, are experienced by approximately 15% and 8% of patients, respectively. Determining the long-term durability of all obesity treatments warrants future research.

CONCLUSIONS AND RELEVANCE

The prevalence of adolescent obesity is approximately 21% in the US. Treatment options for adolescents with obesity include lifestyle modification therapy, pharmacotherapy, and metabolic and bariatric surgery. Intensive lifestyle modification therapy reduces BMI by approximately 3% while pharmacotherapy added to lifestyle modification therapy can attain BMI reductions ranging from 5% to 17%. Surgery is the most effective intervention for adolescents with severe obesity and has been shown to achieve BMI reduction of approximately 30%.

摘要

重要性

肥胖影响了大约 21%的美国青少年,与胰岛素抵抗、高血压、血脂异常、睡眠障碍、抑郁和肌肉骨骼问题有关。青少年时期的肥胖也与成年后患心血管疾病和 2 型糖尿病的死亡率增加有关。

观察结果

12 岁至 18 岁以下青少年的肥胖通常定义为体重指数(BMI)位于第 95 百分位或更高的年龄和性别调整百分位。青少年的综合治疗包括生活方式改变疗法、药物治疗和代谢和减肥手术。生活方式改变疗法包括饮食、体力活动和行为咨询,是一线治疗方法;作为单一疗法,生活方式改变需要超过 26 个接触小时,持续 1 年,才能使 BMI 平均降低约 3%。新型抗肥胖药物,如利拉鲁肽、司美格鲁肽和 phentermine/topiramate,与生活方式改变疗法联合使用,可使 BMI 在 1 年的治疗中平均降低约 5%至 17%。不良反应各不相同,但这些新型抗肥胖药物的严重不良反应罕见。对于严重青少年肥胖(BMI≥第 95 百分位的 120%),手术(Roux-en-Y 胃旁路术和垂直袖状胃切除术)可使 BMI 在 1 年内平均降低约 30%。大约 15%和 8%的患者分别经历轻微和重大围手术期并发症,如再次手术和因脱水住院。需要进一步研究来确定所有肥胖治疗的长期持久性。

结论和相关性

美国青少年肥胖的患病率约为 21%。肥胖青少年的治疗选择包括生活方式改变疗法、药物治疗和代谢和减肥手术。强化生活方式改变疗法可使 BMI 降低约 3%,而药物治疗与生活方式改变疗法联合使用可使 BMI 降低 5%至 17%。手术是治疗严重肥胖青少年最有效的干预措施,已证明可使 BMI 降低约 30%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验